Name

FatiAbGen Inc.

Legal name

FatiAbGen Co., Ltd.

Website

https://fatiabgen.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Sejung

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pipeline Development and Licensing: As a pre-revenue biotech company, FatiAbGen is focused on discovering and developing innovative monoclonal antibody-based therapies. Revenue is expected to come from licensing deals, co-development partnerships, and ultimately product commercialization in oncology and immunology.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

FatiAbGen is a pre-clinical biopharmaceutical company that uses a proprietary antibody engineering platform to discover and develop multi-modality monoclonal antibody-based therapies, including Antibody Drug Conjugates (ADCs) and T Cell-engager bispecific antibodies, targeting oncology and immunology/allergy diseases. The company's lead asset is a superior anti-mesothelin ADC with strong pre-clinical data. FatiAbGen pursues revenue through licensing deals, co-development partnerships with pharma/biotech firms, and academic collaborations.

Product overview

FatiAbGen Inc. is an antibody-based platform company developing multi-modality antibodies for difficult targets in high unmet need diseases in oncology and immunology. The company's portfolio consists of three core areas: ADC (Antibody Drug Conjugates) platform including a lead anti-mesothelin ADC asset with strong pre-clinical data, an Autoimmune Disease Treatment Platform leveraging best-in-class therapeutic antibodies for allergy and immunological disorders, and a Pipeline Assets program for Oncology and Allergy disease treatments. The company operates using its own therapeutic antibody technology platforms and pursues open innovation with external collaborations.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody Drug Conjugate (ADC) Platform Proprietary Antibody Drug Conjugate platform for targeted cancer therapy, including the lead anti-mesothelin ADC asset. Designed to be licensed or co-developed with pharmaceutical and biotech partners for solid tumor indications.
• Anti-Mesothelin ADC (Lead Asset) Superior anti-mesothelin ADC lead candidate targeting mesothelin-expressing solid tumors with high unmet medical need. Currently in pre-clinical stage.
• Autoimmune and Allergy Disease Treatment Platform Therapeutic antibody-based treatments for autoimmune diseases and allergy conditions, leveraging FatiAbGen's proprietary best-in-class therapeutic antibodies and in-licensed technology from Ajou University.
• Pre-Clinical Pipeline Assets (Oncology and Allergy) Broad pre-clinical antibody pipeline spanning oncology and allergy disease targets, available for licensing and co-development with pharmaceutical and biotech partners.

Quantifiable outcome

• Selected as 2023 The 3rd Korea Drug Development Project
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Switzerland Innovation Park Basel Area AGminorOthers · 1 February 2024FatiAbGen International GmbH is located at the Switzerland Innovation Park Basel Area AG, joining the Novartis Campus and Basel area life sciences ecosystem.
• Swiss Business Hub Korea / Switzerland Global Enterprise / Basel Area Business and InnovationminorOthers · 1 February 2024Support organizations that assisted FatiAbGen in establishing its European subsidiary in Basel, Switzerland.
• Y-Biologics Inc.coreStrategic or Co-development Partner · 20 April 2021FatiAbGen and Y-Biologics signed a collaborative R&D term sheet for discovery and co-development of antibody candidates for targets of various cancers. Y-Biologics focuses on novel antibody therapeutics using its human antibody library Ymax-ABL and bispecific antibody platform ALiCE. The collaboration is expected to bolster new discovery and accelerate R&D progress for both companies.
• Chonnam National UniversitycoreStrategic or Co-development Partner · 12 April 2021FatiAbGen and Chonnam National University agreed on joint R&D collaboration to discover novel target cancer cells and build a toxin library, based on bioinformatics.
• Wonkwang UniversitycoreStrategic or Co-development Partner · 8 March 2021FatiAbGen and Wonkwang University agreed on joint R&D collaboration for discovery of new toxin peptide to cure various cancers.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Emerging players

• Adagene: Clinical-stage biotech using AI-driven antibody discovery to develop mono- and bispecific oncology therapeutics; overlaps with FatiAbGen's antibody engineering and bispecific programs.
• ProfoundBio: Clinical-stage company developing next-generation ADCs for solid tumors; comparable to FatiAbGen's lead anti-mesothelin ADC ambition and ADC platform focus.
• Mersana Therapeutics: Clinical-stage ADC developer with proprietary linker and payload platforms targeting oncology; comparable in modality (ADCs) and target indications to FatiAbGen.
• Atreca: Clinical-stage biotech developing novel antibody-based immunotherapies derived from patient immune responses; comparable in being an antibody-discovery platform company pursuing oncology partnerships.
• Mythic Therapeutics: Clinical-stage ADC developer with a focus on solid tumors; comparable in therapeutic area (oncology ADCs) and stage of development to FatiAbGen's lead program.

Direct peers

• Pyxis Oncology: Clinical-stage antibody therapeutics company focused on ADCs and immuno-oncology; a direct comparand and current research collaboration partner of FatiAbGen.
• LegoChem Biosciences: Korean biotech developing ADC platforms including linker and payload chemistry; an existing research collaboration partner of FatiAbGen and a directly comparable ADC-platform peer.
• Y-Biologics: Korean antibody discovery company with a human antibody library and bispecific platform (ALiCE); an active co-development partner of FatiAbGen and a closely comparable antibody-platform peer.

Broad incumbents

• ImmunoGen (now AbbVie): Established ADC pioneer (Elahere for ovarian cancer) now part of AbbVie; sets the standard for ADC commercial economics and represents a likely acquirer/partner for emerging ADC biotechs like FatiAbGen.
• Genmab: Global antibody therapeutics company with validated bispecific platforms (e.g., bispecific T-cell engagers); overlaps directly with FatiAbGen's T-cell engager and bispecific antibody programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FatiAbGen Inc.